Fluvoxamine 100 mg Daily: Moderate Dose
A daily dose of 100 mg fluvoxamine is considered a moderate dose, falling in the middle of the therapeutic range for most indications.
Dosing Context from Guidelines and FDA Labeling
The FDA-approved therapeutic range for fluvoxamine spans 50-300 mg/day 1. Based on this range:
- Low dose: 50-75 mg/day
- Moderate dose: 100-150 mg/day
- High dose: 200-300 mg/day
Evidence Supporting 100 mg as Moderate Dose
For Alzheimer's-related depression, the guideline recommends an initial dose of 50 mg twice daily with a maximum of 150 mg twice daily (300 mg total), positioning 100 mg daily as a mid-range starting point 2.
For pediatric anxiety disorders, the 2020 AACAP guidelines do not specify exact dose categories but note that fluvoxamine has greater potential for drug-drug interactions compared to other SSRIs 3. The therapeutic approach involves starting low and titrating based on response.
For PTSD-associated nightmares, studies used 50 mg/day as a starting dose, titrating to 100-250 mg/day, with the therapeutic range centered around 100-150 mg/day 4.
Clinical Trial Data
In adult OCD studies, patients were titrated to 150 mg/day over two weeks, then adjusted within 100-300 mg/day based on response 1. This positions 100 mg as the lower end of the established therapeutic range.
Research on depression treatment found that 100-150 mg daily produced a 73.7% improvement rate versus 47.1% with 50-75 mg daily, demonstrating that 100 mg represents the threshold for optimal efficacy 5.
Practical Considerations
- 100 mg daily provides adequate therapeutic effect for most indications while minimizing side effects
- This dose allows room for upward titration to 150-200 mg if needed for treatment-resistant cases
- The dose is low enough to reduce risk of discontinuation syndrome compared to higher doses 3
- Drug interaction risk remains significant at all doses due to fluvoxamine's effects on multiple CYP450 enzymes (CYP1A2, CYP2C19, CYP2C9, CYP3A4, CYP2D6) 3
Common Pitfalls
Do not assume 100 mg is a "low" dose simply because it's a round number. The evidence clearly demonstrates this dose produces therapeutic plasma concentrations and clinical efficacy. Conversely, do not consider it "high" - the maximum approved dose is 300 mg/day, making 100 mg solidly in the moderate range 1.